Pint Pharma announces the approval of ORLADEYO® (berotralstat), the first oral therapy indicated to prevent hereditary angioedema (HAE) attacks in adults and children 12 years and older in Peru.

LIMA, Peru–(BUSINESS WIRE)– #angioedemahereditario–It is a great pleasure to announce that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has approved the daily oral use of ORLADEYO® (berotralstat) for prophylaxis of hereditary angioedema (HAE) attacks in adults and children 12 years and older. Hereditary angioedema is a genetic disorder that causes recurrent episodes of sudden, painful swelling of the skin, mucous membranes, and submucosal tissues. Until recently, treatment options for HA